Search results
Results from the WOW.Com Content Network
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [1] [2] Donanemab was developed by Eli Lilly and Company. [3] [4] The most common side effects include amyloid-related imaging abnormalities and headache. [2] Donanemab was approved for medical use in the United States in July 2024.
Three deaths were reported among the people receiving donanemab during the trial which were considered “treatment related”, according to the 2023 paper. One treatment-related death was ...
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [31] [32] Donanemab was developed by Eli Lilly and Company. [33] [34] The most common side effects include amyloid-related imaging abnormalities and headache. [32] Donanemab was approved for medical use in the United States in ...
Lilly's donanemab was declined accelerated approval by the FDA in January 2023, and on March 8, the agency said it would hold a meeting of its advisers to discuss the drug, further delaying its ...
A decision on donanemab has been delayed, with the regulatory agency initially planning to make a call in July, the same time it was approved for use in the U.S., the report said.
The Washington Post submitted a complaint against Coler's registration of the site with GoDaddy under the UDRP, and in 2015, an arbitral panel ruled that Coler's registration of the domain name was a form of bad-faith cybersquatting (specifically, typosquatting), "through a website that competes with Complainant through the use of fake news ...
A new Alzheimer's drug is being hailed as a "turning point" in the fight against the disease, with researchers saying it marks the beginning of a "new era where Alzheimer's could become treatable".
Here are links to possibly useful sources of information about Donanemab. PubMed provides review articles from the past five years (limit to free review articles) The TRIP database provides clinical publications about evidence-based medicine. Other potential sources include: Centre for Reviews and Dissemination and CDC